Fierce Pharma May 16, 2024
Right on the heels of a similar move by Johnson & Johnson, GSK is offloading the rest of its stake in the consumer healthcare business it spun out back in 2022.
GSK plans to sell (PDF) its remaining 4.2% holding in Haleon, representing around 385 million shares, the company said in a Thursday filing.
The shares will be offered to institutional investors by Goldman Sachs and Bank of America Securities, the company said. The sale is expected to raise about 1 billion pounds sterling ($1.26 billion), according to the Financial Times.
GSK completed the spinoff of its consumer health division—formerly a joint venture between the British pharma and Pfizer—in July 2022. At the time, GSK held a roughly 13%...
Today's Sponsors
Today's Sponsor